Stephan Emmerth

Stephan Emmerth

PhD | Director Therapeutic Innovation and BaseLaunch

Tel. +41 61 295 50 17

report Life Sciences
Novartis campus in Basel (img: Wikimedia Commons)

Novartis campus in Basel (img: Wikimedia Commons)


Novartis appoints new oncology head

On February 1, Elizabeth Barrett will succeed to the role of head of oncology at the Basel-based pharmaceutical giant Novartis. She is currently Pfizer’s Global President Oncology.

Barrett succeeds Bruno Strigini, who has stepped down for personal reasons, explained Novartis in a statement.

Before joining Pfizer in 2009, the US citizen occupied numerous leadership positions in pharmaceutical and consumer goods companies.

"Liz is a highly accomplished and recognized oncology and people leader with an impressive record of building successful business organizations in the US, Europe and globally,” commented designated CEO of Novartis, Vasant Narasimhan, in the statement.

He added: “Her long-time commercial pharma industry experience, marketing skills and perspectives make Liz a great fit to further develop our oncology business."

Barrett will be based in Basel, where she will head oncology and join the Novartis management board.  

"I feel honored to join Novartis, a recognized pioneer in the oncology area. It is key to me to contribute to transformative advancements in oncology, and to serve in a highly impactful leadership role to this end," said the future CEO of Novartis Oncology.

Novartis also announced that Robert Kowalski would assume ad interim leadership of the Global Drug Development Organization. The definitive head of the organization will be announced in due course. 


Life Sciences
Cookies uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.